An increasing number of evidence is showing that during prolonged treatment of relapsing-remitting multiple sclerosis (RRMS) with interferon (IFN) beta 1a or IFN beta 1b, the patients may develop serum anti-IFN antibody. It has been argued that some of the RRMS patients receiving IFN beta, who developed antibodies to IFN, lose them over time even though the treatment continues. To gain further insights into this issue, we performed a study to establish what happened to binding antibodies (BAB) and neutralizing antibodies (NAB) in 42 RRMS patients treated for 6 years with IFN beta 1a and/or IFN beta 1b. While the data of BAB analysis did not allow to reach definite conclusions, the results on NAB development confirm that the presence of this type of antibodies is transitory; in fact, most of the positive patients reverted to seronegative, although the IFN treatment is still ongoing; the only patients who were positive for NAB at 6 years of treatment are those whose serum contains high concentration of them. The paper also shows that patients lose antibodies to IFN independently on the type of IFN used for the treatment. In conclusion, the data indicate that the disappearance of the anti-IFN antibodies from the serum while the patients are still undergoing IFN treatment depends on the titer of antibodies but not on the type of IFN administered. (C) 2003 Elsevier Science B.V. All rights reserved.

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years / Francesca, Bellomi; Scagnolari, Carolina; Valentina, Tomassini; Claudio, Gasperini; Andrea, Paolillo; Pozzilli, Carlo; Antonelli, Guido. - In: JOURNAL OF THE NEUROLOGICAL SCIENCES. - ISSN 0022-510X. - STAMPA. - 215:1-2(2003), pp. 3-8. [10.1016/s0022-510x(03)00173-4]

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

SCAGNOLARI, CAROLINA;POZZILLI, Carlo;ANTONELLI, Guido
2003

Abstract

An increasing number of evidence is showing that during prolonged treatment of relapsing-remitting multiple sclerosis (RRMS) with interferon (IFN) beta 1a or IFN beta 1b, the patients may develop serum anti-IFN antibody. It has been argued that some of the RRMS patients receiving IFN beta, who developed antibodies to IFN, lose them over time even though the treatment continues. To gain further insights into this issue, we performed a study to establish what happened to binding antibodies (BAB) and neutralizing antibodies (NAB) in 42 RRMS patients treated for 6 years with IFN beta 1a and/or IFN beta 1b. While the data of BAB analysis did not allow to reach definite conclusions, the results on NAB development confirm that the presence of this type of antibodies is transitory; in fact, most of the positive patients reverted to seronegative, although the IFN treatment is still ongoing; the only patients who were positive for NAB at 6 years of treatment are those whose serum contains high concentration of them. The paper also shows that patients lose antibodies to IFN independently on the type of IFN used for the treatment. In conclusion, the data indicate that the disappearance of the anti-IFN antibodies from the serum while the patients are still undergoing IFN treatment depends on the titer of antibodies but not on the type of IFN administered. (C) 2003 Elsevier Science B.V. All rights reserved.
2003
binding antibody; interferon beta 1a; interferon beta 1b; neutralizing antibody; relapsing-remitting multiple sclerosis
01 Pubblicazione su rivista::01a Articolo in rivista
Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years / Francesca, Bellomi; Scagnolari, Carolina; Valentina, Tomassini; Claudio, Gasperini; Andrea, Paolillo; Pozzilli, Carlo; Antonelli, Guido. - In: JOURNAL OF THE NEUROLOGICAL SCIENCES. - ISSN 0022-510X. - STAMPA. - 215:1-2(2003), pp. 3-8. [10.1016/s0022-510x(03)00173-4]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/358589
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 57
  • ???jsp.display-item.citation.isi??? 53
social impact